ISRCTN13282459进行中（未招募）2 期
Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy
Institute of Cancer Research Clinical Trial & Statistics Unit0 个研究点目标入组 42 人开始时间: 2023年10月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Patients =18 years of age (Updated 07/11/2023: previously =16 years of age)
- •2. Histologically confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer
- •3. Radiological disease progression whilst on, or following, any prior PARP inhibitor therapy. The PARP inhibitor is required to have been the patient’s last systemic therapy
- •4. Minimum duration of 6 months PARP inhibitor therapy as first-line therapy or treatment for recurrent disease
- •5. =3 lesions of progressive disease
- •6. Each lesion to undergo SBRT <4 cm axial diameter, and feasible for SBRT as discussed in the virtual SOPRANO virtual MDT (vMDT) meeting.
- •7. Measurable disease by RECIST criteria v1.1, which can be accurately assessed at baseline by CT or MRI. Patients with CA125 progression in the absence of measurable disease will NOT be eligible
- •8. No contra-indication to restarting a PARP inhibitor
- •9. Patients for whom surgery for recurrent disease is not planned.
- •10. Adequate baseline organ function to allow SBRT to all relevant targets as deemed by the investigator. Note: For Patients randomised to the SBRT followed by the Niraparib Cohort confirm the following prior to Niraparib initiation; Absolute neutrophil count: =1,500/µL, Platelets: =100,000/µL, Hemoglobin: =9 g/dL
- •11. ECOG performance status of 0 or 1
- •12. Predicted life expectancy = 6 months
- •13. Women of child-bearing potential who are confirmed NOT to be pregnant. This should be evidenced by a negative urine or serum pregnancy test within 72 hours prior to the start of trial treatment. Patients will be considered to be not of child-bearing potential if they are:
- •13.1. Post-menopausal - defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments, OR women under 50 years old who have been amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments and have serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and plasma oestradiol levels in the post-menopausal range for the institution
- •13.2. Able to provide documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- •13.3. Radiation or chemotherapy-induced oophorectomy or menopause with >1 year since last menses
- •14. Willingness to commit to scheduled visits, treatment plans, laboratory tests and trial procedures
- •15. Histological tissue specimen (tissue block or 8-10 unstained slides) must be available prior to commencing SBRT (specimen can be the sample at diagnosis or taken at relapse or progression). Otherwise, a biopsy must be carried out to obtain sufficient tissue for translational analyses
- •16. Able to swallow, absorb and retain oral medication
- •17. Able to provide written, informed consent
排除标准
- •1. Co-morbidities which would preclude the safe use of SBRT
- •2. Progressing or newly diagnosed brain metastases identified at the time of trial entry, not amenable to radical surgery or stereotactic radiosurgery. Previously treated brain metastases (i.e. palliative radiotherapy or systemic therapy) which have remained clinically and radiologically stable for =6 months are permissible
- •3. Prior radiotherapy near the oligometastatic/oligoprogressive lesion precluding ablative SBRT. Suitability of lesions for ablative SBRT as part of the trial defined in section 6.1 of this document and will be determined by the SOPRANO virtual MDT
- •4. Treatment with any other investigational medicinal product within the 4 weeks prior to trial entry
- •5. Pregnant or lactating women
- •6. Women of childbearing age and potential who are not willing to use a highly effective contraceptive measure as detailed in protocol Section 5.5
- •7. Any unresolved toxicities from prior therapy should be no greater than CTCAE Grade 1 with the exception of Grade 2 alopecia or chemo-induced neuropathy at trial entry
- •8. Clinical/radiological evidence of bowel obstruction (e.g. hospitalisation) or symptoms of sub-acute bowel obstruction within 6 weeks prior to trial entry
- •9. Any other malignancy which has been active or treated within the past 3 years, with the exception of non-melanoma skin cancer. If prior treatment for another malignancy has taken place, then confirmation of ovarian/fallopian tube/peritoneal cancer progression is required e.g. biopsy, and discussion with the Chief Investigator and SBRT Lead
- •10. Judgment by the Investigator that the patient is unsuitable to participate in the trial and/or the patient is unlikely to comply with trial procedures, restrictions and requirements
研究者
相似试验
招募中
3 期
The CONSOLE Trial - A Randomised trial for the treatment of painful bony metastases not located in the spine using Conventional or Stereotactic RadiotherapyMetastatic CancerCancer - Any cancerACTRN12622001200774Icon Cancer Foundation146
进行中（未招募）
不适用
Stereotactic accelerated radiotherapy concurrent with Temozolomide chemotherapy in newly diagnosed glioblastoma - NDEUCTR2009-015614-21-ITISTITUTO NEUROLOGICO CARLO BESTA
已完成
2 期
Addition of stereotactic radiotherapy to the standard FOLFIRINOX treatment in locally advanced pancreatic cancer patients to determine efficacy and feasability (LAPC-1)locally advanced pancreatic carcinoma1001567410017991Pancreatic cancerNL-OMON44466Stichting Leveronderzoek51
Unknown
不适用
Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.locally advanced pancreatic cancerpancreatic neoplasmFOLFIRINOXstereotactic radiotherapyNL-OMON27030Foundation for Liver and Gastrointestinal Research51
已完成
2 期
Stereotactic body radiotherapy followed by surgical stabilization for patients with painful unstable spinal metastases: First-in-man study according to the IDEAL recommendationsmetastatic spine tumorspinal metastases100059591002747610005944NL-OMON42087niversitair Medisch Centrum Utrecht13